Ironwood Pharmaceuticals, Inc.
NASDAQ:IRWDDrug Manufacturers - Specialty & Generic
+$0.01 today
- Market cap
- $791.33M
- Beta
- 0.24
- P/E (TTM)
- 5.6
- EPS (TTM)
- $0.63
Volume 2.22M
Average 2.35M
IRWD Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Ironwood Pharmaceuticals, Inc.NASDAQ: IRWD
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $3.65M fell 31.0% year over year, behind the -11.2% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 69.5% from the prior quarter. Over 3 fiscal years it compounded at -13.9% a year.
Context
- Stock-based compensation amounted to 5.8% of revenue in FY2025, down 2.7 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -31.0% toward the trailing-twelve-month pace of -11.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 17.25M USD
- Year-over-year change
- -42.2%
- 4-year CAGR
- -6.2%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.25M | -42.2% |
| FY2024 | 2024-12-31 | 29.85M | -6.7% |
| FY2023 | 2023-12-31 | 32.01M | +18.3% |
| FY2022 | 2022-12-31 | 27.05M | +21.4% |
| FY2021 | 2021-12-31 | 22.28M | — |
Stock-Based Compensation vs competitors
How IRWD compares with its peers on the latest reported figures
- IRWD's LTM Mar 2026 stock-based compensation of $23.75M is the smallest of the 3 companies compared; the peer median is $50.66M.
- Its year-over-year change of -11.2% is the lowest of 3, against a peer median of +28.9%.
- Stock-based compensation amounts to 6.6% of revenue for IRWD, versus a peer median of 33.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $51.03M | +21.9% | +65.8% | 11.9% | |
| LTM Sep 2026 | $50.3M | +35.9% | +74.2% | 55.6% | |
| LTM Mar 2026 | $23.75M | -11.2% | -13.9% | 6.6% | |
| Peer median (excluding IRWD) | $50.66M | +28.9% | +70.0% | 33.8% | |
Competitors are the stored peer set for IRWD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 528.45M | 175.07M | (1B) | 880K | 24.02M |
| Depreciation & Amortization | 1.5M | 1.42M | 1.58M | 2.01M | 1.88M |
| Deferred Income Tax | (333.29M) | 65.74M | 72.64M | 68.09M | 40.8M |
| Stock-Based Compensation | 22.28M | 27.05M | 32.01M | 29.85M | 17.25M |
| Change in Working Capital | 17.73M | 2.82M | 11.28M | 739K | 39.65M |
| Accounts Receivables | 7.71M | 7.99M | 924K | 47.24M | 35.15M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (2.64M) | (8.12M) | 12.38M | (20.21M) | 6.2M |
| Other Working Capital | 12.66M | 2.94M | (2.03M) | (26.29M) | (1.7M) |
| Other Non-Cash Items | 25.23M | 1.67M | 1.07B | 1.98M | 3.45M |
| Operating Cash Flow | 261.9M | 273.76M | 183.43M | 103.55M | 127.04M |
| Capital Expenditures | (265K) | (136K) | (273K) | (142K) | (34K) |
| Acquisitions (Net) | 0 | 0 | (1.03B) | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (265K) | (136K) | (1.03B) | (142K) | (34K) |
| Debt Repayment | 0 | (120.7M) | 300M | (115M) | 0 |
| Common Stock Issued | 19.58M | 9.54M | 6.36M | 11.01M | 216K |
| Common Stock Repurchased | (24.13M) | (126.39M) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 19.58M | 9.54M | (29.2M) | (2.98M) | 0 |
| Financing Cash Flow | (4.55M) | (237.55M) | 277.16M | (106.97M) | 216K |
| Effect of Forex Changes | 0 | 0 | (53K) | (32K) | (329K) |
| Net Change in Cash | 257.08M | 36.07M | (565.78M) | (3.6M) | 126.9M |
| Free Cash Flow | 261.63M | 273.63M | 183.15M | 103.41M | 127.01M |
Ironwood Pharmaceuticals, Inc.
NASDAQ:IRWD
Intrinsic Alpha fair value
Locked
Current Price
$4.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.